Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J. Randolph Hecht
a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination With FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma
Oncologist
Cancer Research
Medicine
Oncology
Related publications
A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
A Randomised, Double-Blind, Placebo-Controlled Multi-Centre Phase III Trial of XELIRI/FOLFIRI Plus Simvastatin for Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
Becaplermin Gel in the Treatment of Pressure Ulcers: A Phase II Randomized, Double-Blind, Placebo-Controlled Study
Wound Repair and Regeneration
Dermatology
Surgery
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Tremelimumab for Second and Third Line Treatment in Patients With Unresectable Pleural or Peritoneal Mesothelioma
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Therapeutic Effect of Oral CF101 in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Phase II Study
Immunome Research
Sarilumab for the Treatment of Ankylosing Spondylitis: Results of a Phase II, Randomised, Double-Blind, Placebo-Controlled Study (ALIGN)
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
A Randomized Double-Blind Placebo-Controlled Trial of Probiotics in Post-Surgical Colorectal Cancer
BMC Gastroenterology
Medicine
Gastroenterology
Aripiprazole for the Treatment of Methamphetamine Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial
Addiction
Medicine
Psychiatry
Mental Health
A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
